Overview

Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Status:
Active, not recruiting
Trial end date:
2024-01-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (BOS).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Incyte Corporation